MAPS recently published the results of their Phase 3B MDMA clinical trial (Nature Medicine, 14 Sept. 2023). The outcome of the trial was positive, and suggested that MDMA assisted therapy reduced PTSD symptoms and functional impairment in participants with moderate to severe PTSD, in addition to being generally well tolerated.
So what is next for MAPS and MDMA? And what are the legal issues surrounding MDMA-assisted therapy?
Join ATMA, along Dr. Scott Shannon as he discusses MAPS Phase 3 clinical trial, MAPS protocols for MDMA, and the opportunities and challenges ahead for legally treating PTSD using MDMA-assisted therapy.
Dr. Scott Shannon will also discuss training in MDMA-assisted therapy as he will be joining the ATMA instructor team to help expand its training expertise on using MDMA to treat PTSD.
ATMA will facilitate this live info session with Q&A.
What we will discuss:
